Reconnecting

The current page stays visible while onset.to reconnects in the background.

After FDA Approval: The Insurance, Workforce and State Policy Challenges Facing Psychedelic Therapy

Open original

Potential FDA approval of psychedelic-assisted therapy would begin a difficult effort to make treatment accessible, rather than guarantee access. Logan Davidson argues that federal safety requirements may not align with state programs, while insurers face unresolved billing and reimbursement questions. Veterans could encounter delays as the VA reviews formularies, trains providers and expands services across facilities. A national shortage of mental health workers, differing state rules on provider qualifications, and uneven rural access could further limit availability. Approval is not guaranteed and would initially cover specific indications, making coordination among regulators, payers, states and training programs essential.